openPR Logo
Press release

After more than 7 years of treatment for Parkinson's syndrome, trembling and stiffness are significantly reduced after robotic surgery

12-13-2024 10:58 PM CET | Health & Medicine

Press release from: ABNewswire

After more than 7 years of treatment for Parkinson's syndrome,

When it comes to Parkinson disease, many people think of Parkinson syndrome. In life, many people who do not have professional medical knowledge cannot clearly distinguish between these two diseases, and even confuse or completely equate them in many cases. .So what kind of disease is Parkinsonism and what are the specific effects it has on people?Today we will learn about it through a case.

Image: https://ecdn6.globalso.com/upload/p/857/image_other/2024-10/h1-1.png

Aunt Li is 68 years old this year. Seven years ago, there was no obvious cause for involuntary shaking of the lower left limb, which was a static tremor. She visited a hospital without a clear diagnosis and the drug treatment was ineffective.After half a year, it developed to the upper left limb and there was also a static tremor, slow movement, a slight stiffness of the limbs, and a loss of smell.Aunt Li, who has sought medical treatment for many times, developed involuntary shaking and stiffness of her limbs two years ago, and her movement was slow (difficult to start and slow to turn around). The symptoms were mainly on the left side.

For further treatment, he came to our hospital.After a joint diagnosis by several experts in our hospital, it was found that Aunt Li is not a simple Parkinsonism, but belongs to Parkinsonism syndrome. There is an essential difference between the two.Parkinsonism also includes other diseases caused by other reasons that are similar to the symptoms of Parkinsonism.After fully communicating with Aunt Li herself and her family, it was decided that Professor Tian Zengmin would perform robotic stereotactic surgery for her to solve the problem of shaking and slow movement of the left limb.The difference between Parkinsonism and Parkinsonism1 Different age of onsetParkinsonism can occur in any age group, and the youngest patient with Parkinsonism that our hospital has ever treated is only 26 years old.Parkinson's disease usually develops in middle-aged and elderly people. In recent years, with the increase of social pressure, it has also shown a trend of youth.2 Different clinical manifestationsClinically, in addition to the same manifestations as Parkinson's disease such as slow movement, sluggish expression, increased muscle tone, tremor, etc., Parkinson's syndrome often has the same manifestations left over from the original onset.

The 26-year-old juvenile patient with Parkinson's syndrome mentioned earlier is also accompanied by hereditary spastic paraplegia.The imaging manifestations of Parkinson's disease are not characteristic, while Parkinson's syndrome often has corresponding changes or characteristic changes.3The etiology and pathogenesis are different.The pathological changes of Parkinson's disease are mainly due to the degeneration of dopamine neurons in the melanoplasm of the midbrain, so that they cannot produce enough dopamine and become ill.On the other hand, Parkinson's syndrome is a syndrome of known etiology. The pathological changes in the brain are caused by lesions of the brain, the melanoplasm and striatum pathways of the midbrain, and degeneration of dopamine neurons, resulting in insufficient production of dopamine or inability to transmit dopamine to maintain normal nerve function. Caused.4 Different treatments.The treatment of Parkinsonism is not the same as the treatment of Parkinsonism. Early drug treatment has a better effect on Parkinsonism, but the effect on Parkinsonism is poor.Technical introduction.

Robotic stereotactic surgery.In 2019, Nuolai International Medical Center introduced robot-assisted frameless brain stereotactic surgery. With the help of medical image scanning, three-dimensional visualization, multi-modal image fusion and other technologies, the brain lesion area can be accurately found.After planning the puncture path to accurately reach the surgical target, and solving the lesion problem through thermal coagulation, biological therapy, etc., brain diseases can be fundamentally treated, and the effect is very mature and successful.Technical advantage.Compared with the trauma caused by traditional craniotomy, frameless brain stereotactic surgery has the advantages of scientific and technological innovation in four aspects: minimally invasive, accurate, efficient and safe.The entire operation takes only 30 minutes, the wound is only 2-3 mm, and the positioning accuracy reaches 1 mm. After 2-3 days of postoperative observation, you can be discharged from the hospital.The risk rate of surgery such as infection and bleeding is much lower than 1%, and it has obvious effects on nearly 100 kinds of extranasal diseases such as cerebral palsy, epilepsy, cerebral hemorrhage, and Parkinsonism.

Image: https://ecdn6.globalso.com/upload/p/857/image_other/2024-10/h2.pngImage: https://ecdn6.globalso.com/upload/p/857/image_other/2024-10/h3.pngImage: https://ecdn6.globalso.com/upload/p/857/image_other/2024-10/h4.png

After the operation, combined with a series of symptomatic treatments such as drugs and rehabilitation, Aunt Li's upper left limb trembling, stiffness and other symptoms were significantly reduced, and walking was more flexible than before. The patient and his family were very satisfied with the treatment effect.

Media Contact
Company Name: Nuolai Biomedical Technology Co., Ltd.
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=after-more-than-7-years-of-treatment-for-parkinsons-syndrome-trembling-and-stiffness-are-significantly-reduced-after-robotic-surgery]
Phone: +86 18500761086
Address:Tai'an, China: No. 282, Tianzhufeng Road, Taishan District, Taian City, Shandong Province Beijing Branch Office: Chang'an Taihe, Dongcheng District
City: Beijing
Country: China
Website: https://www.bjnuolai.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release After more than 7 years of treatment for Parkinson's syndrome, trembling and stiffness are significantly reduced after robotic surgery here

News-ID: 3787635 • Views:

More Releases from ABNewswire

Empire Paving Partners with 1-800-ASPHALT Service to Enhance Customer Access Across Northeast Ohio
Empire Paving Partners with 1-800-ASPHALT Service to Enhance Customer Access Acr …
Cleveland commercial paving contractor secures exclusive vanity number rights for greater Cleveland region Cleveland, OH - October 28, 2025 - Empire Paving, a leading commercial asphalt contractor serving Northeast Ohio for over 20 years, today announced its exclusive partnership with the 1-800-ASPHALT vanity phone number service for three area codes covering the Cleveland region. The strategic investment reinforces Empire Paving's commitment to customer convenience, providing commercial property owners and businesses with an
Powell's Plumbing & Air Delivers Exceptional Air Conditioning Repair Across Norfolk, VA
Powell's Plumbing & Air Delivers Exceptional Air Conditioning Repair Across Norf …
In the warm and humid climate of Norfolk, VA, staying comfortable indoors often depends on how well an air conditioning system performs. When cooling units start to malfunction, timely air conditioning repair becomes essential to prevent costly damage and discomfort. A professional team like Powell's Plumbing & Air ensures that residents enjoy consistent comfort throughout every season. With years of experience, the company understands how quickly heat and humidity can
Mydriasis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia, Taejoon Pharma
Mydriasis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | …
The Key Mydriasis Companies in the market include - Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others. DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis
Lyme Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Laboratories, Inc., Covance Inc.F. Hoffmann-La Roche AG
Lyme Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Miles …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Lyme Disease pipeline constitutes 7+ key companies continuously working towards developing 7+ Lyme Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Lyme Disease Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lyme Disease Market. The Lyme Disease Pipeline report

All 5 Releases


More Releases for Parkinson

Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025? The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period? The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market? In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market? In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $1.43 billion
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%. Increasing Geriatric Population Driving Demand: The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,